R3

R3 Bio is a private biotechnology company developing human-relevant cell-based research platforms for preclinical research. The company combines cellular reprogramming, human stem-cell-derived systems, integrated biological signaling approaches, and computational analysis to build in vitro models intended to improve biological prediction and support New Approach Methodologies. Its near-term focus appears to be experimental cell-culture systems and model validation rather than a traditional therapeutic drug pipeline. The company positions its work around reducing reliance on animal studies where scientifically appropriate and supporting more regulatory-aligned preclinical decision-making. R3 Bio is headquartered in Cambridge, Massachusetts and appears to be an early-stage, venture-backed company.